RARX - Ra Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
5,500
2,500
0
4,928
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
71,796
54,449
45,251
27,928
Selling General and Administrative
19,514
14,439
9,778
5,024
Total Operating Expenses
91,310
68,888
55,029
32,952
Operating Income or Loss
-85,810
-66,388
-55,029
-28,024
Interest Expense
-
-
0
0
Total Other Income/Expenses Net
2,221
-38
-74
-967
Income Before Tax
-82,125
-64,962
-54,458
-28,882
Income Tax Expense
-
-19
-19
-18
Income from Continuing Operations
-82,106
-64,943
-54,439
-28,864
Net Income
-82,106
-64,943
-54,439
-28,864
Net Income available to common shareholders
-82,106
-64,943
-54,439
-28,864
Reported EPS
Basic
-
-2.06
-2.41
-6.98
Diluted
-
-2.06
-2.41
-6.98
Weighted average shares outstanding
Basic
-
31,542
22,591
4,135
Diluted
-
31,542
22,591
4,135
EBITDA
-
-64,791
-52,934
-27,608